Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT04701619

Immuno-inflammatory Profile and Response to Ischemic Stroke Reperfusion Therapies (IMMUNOSTROKE)

IMMUNOSTROKE study aims to describe the immuno-inflammatory and thrombo-inflammatory profiles during the course of AIC management by reperfusion treatment and to monitor changes in these different parameters over time. Post-hoc analyses will make it possible to correlate the immuno-inflammatory and thrombo-inflammatory profiles and their evolution with the clinical outcome in terms of post-AIC functional and cognitive disability.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient over 18 years of age
  • Presenting with an ACS for which reperfusion therapy is indicated according to European and North American recommendations (IV thrombolysis or mechanical thrombectomy or a combination of both)
  • Having received informed information about the study and having signed a consent form to participate in the study (if this is not possible: information and consent from a trusted person or family member if present; emergency inclusion if absent)
  • Affiliated with or beneficiary of a social security system

Exclusion criteria

  • Contraindication to performing a brain MRI (claustrophobia, pacemaker, or other implantable device contraindicating the performance of an MRI)
  • Intracranial hemorrhage associated with AIC on initial imaging

Immunosuppressive treatment or corticosteroid therapy at patient admission

  • Pre-existing neurological disability limiting neurological assessment at 3 months (mRS>2 at admission)
  • Known and diagnosed dementia pre-existing at the time of the AIC
  • Absolute or relative contraindication to the injection of gadolinium (history of true allergic reaction or intolerance to gadobutrol, renal failure with creatinine clearance <15mL/min, pregnant or breastfeeding women)
  • Patient treated by another institution and referred solely for mechanical thrombectomy
  • Patient benefiting from legal protection measures

Treatment and study plan

Immuno-inflammatory profile description in patients with ischemic stroke

Other

Patients will be evaluated for inflammatory biomarkers at inclusion, at 24-48 hours of reperfusion treatment , at 72 hours, at 7 days or at discharge if before D7, at discharge if after D7, at 3 months and at 1 year.The biomarkers will be measured using ELISA panels for inflammatory biomarkers

Primary outcomes

  1. Immuno-inflammatory profile description in patients with ischemic stroke and eligible for reperfusion treatment

    Time frame: Up to year

    Patients will be evaluated for inflammatory biomarkers at inclusion, at 24-48 hours of reperfusion treatment , at 72 hours, at 7 days or at discharge if before D7, at discharge if after D7, at 3 months and at 1 year.The biomarkers will be measured using ELISA preconfigurated panels for inflammatory biomarkers.

Study contacts

Contact information is provided by the study sponsor or research team.

Amélie YAVCHITZ, MD, PhD

CONTACT

[email protected]

01 48 03 64 54 ext. + 33

Benjamin MAIER, Professor, MD, PhD

CONTACT

[email protected]

01 48 03 65 56 ext. + 33

Sponsors and collaborators

Lead sponsor

Fondation Ophtalmologique Adolphe de Rothschild

Network

Registry information

Official study title

Immuno-inflammatory Profile and Response to Ischemic Stroke Reperfusion Therapies

Acronym: IMMUNOSTROKE

Important dates

Study start
2026
Primary completion
2027
Study completion
2028
First posted
Jan 8, 2021
Registry last updated
Jan 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.